Tenaya Therapeutics (TNYA) Net Income towards Common Stockholders (2020 - 2026)

Tenaya Therapeutics' Net Income towards Common Stockholders history runs 7 years deep, the most recent figure standing at -$19.3 million for Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 28.26% year-over-year to -$19.3 million in Q1 2026; TTM through Mar 2026 was -$83.0 million, a 21.52% increase from a year earlier, with the FY2025 full-year figure at -$90.6 million, up 18.48% from the prior year.
• Net Income towards Common Stockholders grew to -$19.3 million in Q1 2026 per TNYA's latest filing, from -$20.2 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at -$19.3 million in Q1 2026 and bottomed at -$33.5 million in Q4 2022.
• The 5-year median for Net Income towards Common Stockholders is -$29.1 million (2023), against an average of -$27.6 million.
• Across the five-year window, Net Income towards Common Stockholders tumbled 137.1% in 2022 and climbed 28.26% in 2026, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$33.5 million in 2022, then gained by 10.68% to -$29.9 million in 2023, then grew by 20.37% to -$23.8 million in 2024, then climbed by 15.36% to -$20.2 million in 2025, then grew by 4.48% to -$19.3 million in 2026.
• Per Business Quant, the three latest TNYA Net Income towards Common Stockholders figures stand at -$19.3 million (Q1 2026), -$20.2 million (Q4 2025), and -$20.3 million (Q3 2025).